Matches in SemOpenAlex for { <https://semopenalex.org/work/W2897332214> ?p ?o ?g. }
- W2897332214 endingPage "111" @default.
- W2897332214 startingPage "101" @default.
- W2897332214 abstract "BackgroundPrevious real-world comparative research of MS disease modifying therapies (DMTs) in the overall population has suggested dimethyl fumarate (DMF) to be comparable to fingolimod (FTY) and more efficacious than teriflunomide (TERI) in reducing relapses. However, there is limited comparative evidence in patients switching from platform DMTs in the US. The objective of the study was to compare the annualized relapse rate (ARR) and risk of relapse in MS patients who have switched from a platform therapy to DMF, FTY, or TERI.MethodsMS patients (18–65 years old) initiating an oral DMT from June 2013 to March 2015 were identified from the Truven MarketScan® Commercial Claims Database. The index date was the date of first oral DMT fill. Patients were required to have: continuous enrollment in the database for 12 months pre-index date and ≥3 months post-index date; ≥1 MS diagnosis over the pre-index period; discontinuation of a platform DMT with no evidence of oral or infusion DMTs over the pre-index period; and adherence to the index drug for ≥90 days. DMF patients were propensity-score matched (PSM) 3:1 to FTY and to TERI based on age, gender, region, a claims-based MS severity measure, ARR, and number of hospitalizations over the pre-index period. Patients were censored when they dropped out of the database or at the end of the study period (March 31, 2016). Post-index relapses were annualized.ResultsThe database included 20,311 oral DMT users. After applying the study criteria, the PSM yielded 1602:534 switch patients for the DMF–FTY matched cohort. DMF–FTY patients were well-matched on all covariates: age (mean = 44 for both), gender (28% vs. 26% male, respectively), MS severity measure (0.99 vs. 1.08), and baseline ARR (0.40 vs. 0.44). PSM yielded 833:279 switch patients for the DMF–TERI match. DMF–TERI patients were well-matched on all covariates: age (mean = 50), gender (24% vs. 25% male), MS severity measure (0.86 vs. 0.99), and baseline ARR (0.23 vs. 0.30). The standardized differences confirmed balance across all covariates for matched cohorts. The matched DMF–FTY cohorts had comparable post-index ARR (Rate Ratio [RR] = 1.07 [95% Cl: 0.861, 1.328]) and risk of relapse (Hazard Ratio [HR ]= 0.996 [95% CI: 0.803, 1.236]). Post-index ARR was significantly lower with DMF in comparison to TERI (RR = 0.667 [0.486, 0.914]). The risk of relapse was also significantly lower when switching to DMF than TERI (HR = 0.679 [0.503, 0.917]).ConclusionIn this analysis, the effectiveness profiles for those oral DMT users specifically switching from platform therapies are consistent with findings from previous research conducted among all oral DMT users, regardless of prior therapy." @default.
- W2897332214 created "2018-10-26" @default.
- W2897332214 creator A5015543357 @default.
- W2897332214 creator A5018157909 @default.
- W2897332214 creator A5023283071 @default.
- W2897332214 creator A5030923235 @default.
- W2897332214 creator A5032654810 @default.
- W2897332214 creator A5045977047 @default.
- W2897332214 creator A5060518146 @default.
- W2897332214 creator A5066404216 @default.
- W2897332214 creator A5066420218 @default.
- W2897332214 creator A5081502666 @default.
- W2897332214 date "2019-01-01" @default.
- W2897332214 modified "2023-10-18" @default.
- W2897332214 title "Comparative effectiveness of dimethyl fumarate versus fingolimod and teriflunomide among MS patients switching from first-generation platform therapies in the US" @default.
- W2897332214 cites W153101962 @default.
- W2897332214 cites W1825094415 @default.
- W2897332214 cites W1967838438 @default.
- W2897332214 cites W2014094373 @default.
- W2897332214 cites W2014799253 @default.
- W2897332214 cites W2031099852 @default.
- W2897332214 cites W2034948055 @default.
- W2897332214 cites W2043591841 @default.
- W2897332214 cites W2053881211 @default.
- W2897332214 cites W2067338532 @default.
- W2897332214 cites W2072173083 @default.
- W2897332214 cites W2087206336 @default.
- W2897332214 cites W2093009907 @default.
- W2897332214 cites W2104948944 @default.
- W2897332214 cites W2118735809 @default.
- W2897332214 cites W2132555717 @default.
- W2897332214 cites W2133329597 @default.
- W2897332214 cites W2133392888 @default.
- W2897332214 cites W2140240975 @default.
- W2897332214 cites W2179093540 @default.
- W2897332214 cites W2193056371 @default.
- W2897332214 cites W2418089672 @default.
- W2897332214 cites W2489492976 @default.
- W2897332214 cites W2530203323 @default.
- W2897332214 cites W2587994165 @default.
- W2897332214 cites W2591887102 @default.
- W2897332214 cites W2744488360 @default.
- W2897332214 cites W2776524664 @default.
- W2897332214 cites W841680093 @default.
- W2897332214 doi "https://doi.org/10.1016/j.msard.2018.09.038" @default.
- W2897332214 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30368221" @default.
- W2897332214 hasPublicationYear "2019" @default.
- W2897332214 type Work @default.
- W2897332214 sameAs 2897332214 @default.
- W2897332214 citedByCount "41" @default.
- W2897332214 countsByYear W28973322142019 @default.
- W2897332214 countsByYear W28973322142020 @default.
- W2897332214 countsByYear W28973322142021 @default.
- W2897332214 countsByYear W28973322142022 @default.
- W2897332214 countsByYear W28973322142023 @default.
- W2897332214 crossrefType "journal-article" @default.
- W2897332214 hasAuthorship W2897332214A5015543357 @default.
- W2897332214 hasAuthorship W2897332214A5018157909 @default.
- W2897332214 hasAuthorship W2897332214A5023283071 @default.
- W2897332214 hasAuthorship W2897332214A5030923235 @default.
- W2897332214 hasAuthorship W2897332214A5032654810 @default.
- W2897332214 hasAuthorship W2897332214A5045977047 @default.
- W2897332214 hasAuthorship W2897332214A5060518146 @default.
- W2897332214 hasAuthorship W2897332214A5066404216 @default.
- W2897332214 hasAuthorship W2897332214A5066420218 @default.
- W2897332214 hasAuthorship W2897332214A5081502666 @default.
- W2897332214 hasBestOaLocation W28973322141 @default.
- W2897332214 hasConcept C126322002 @default.
- W2897332214 hasConcept C203014093 @default.
- W2897332214 hasConcept C2776036978 @default.
- W2897332214 hasConcept C2776819417 @default.
- W2897332214 hasConcept C2777703276 @default.
- W2897332214 hasConcept C2778715236 @default.
- W2897332214 hasConcept C2779134260 @default.
- W2897332214 hasConcept C2780640218 @default.
- W2897332214 hasConcept C2781004633 @default.
- W2897332214 hasConcept C2908647359 @default.
- W2897332214 hasConcept C2910384678 @default.
- W2897332214 hasConcept C512399662 @default.
- W2897332214 hasConcept C71924100 @default.
- W2897332214 hasConcept C99454951 @default.
- W2897332214 hasConceptScore W2897332214C126322002 @default.
- W2897332214 hasConceptScore W2897332214C203014093 @default.
- W2897332214 hasConceptScore W2897332214C2776036978 @default.
- W2897332214 hasConceptScore W2897332214C2776819417 @default.
- W2897332214 hasConceptScore W2897332214C2777703276 @default.
- W2897332214 hasConceptScore W2897332214C2778715236 @default.
- W2897332214 hasConceptScore W2897332214C2779134260 @default.
- W2897332214 hasConceptScore W2897332214C2780640218 @default.
- W2897332214 hasConceptScore W2897332214C2781004633 @default.
- W2897332214 hasConceptScore W2897332214C2908647359 @default.
- W2897332214 hasConceptScore W2897332214C2910384678 @default.
- W2897332214 hasConceptScore W2897332214C512399662 @default.
- W2897332214 hasConceptScore W2897332214C71924100 @default.
- W2897332214 hasConceptScore W2897332214C99454951 @default.
- W2897332214 hasFunder F4320306078 @default.
- W2897332214 hasFunder F4320306161 @default.
- W2897332214 hasFunder F4320308604 @default.